Inpharmatica in PharmaCarta partnership with Pfizer
Drug discovery company Inpharmatica has reached a series of agreements to provide Pfizer with access to four core components of its PharmaCarta gene-to-candidate technology platform, which facilitates target selection through drugability assessment, linked to electronic identification of potential compounds biased for good drug-like characteristics.
Drug discovery company Inpharmatica has reached a series of agreements to provide Pfizer with access to four core components of its PharmaCarta gene-to-candidate technology platform, which facilitates target selection through drugability assessment, linked to electronic identification of potential compounds biased for good drug-like characteristics.
Pfizer will gain access to: StARLITe - a database containing 20 years of curated medicinal chemistry information on compound structure and bioactivity linked to targets; DrugStore - a curated database of all known drugs, linked with their targets; and Admensa - Inpharmatica's proprietary technology for assessing the ADME characteristics of therapeutic compounds and compound libraries.
The financial terms of the agreement have not been disclosed.